Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

Archana Jastorff,Arangassery Rosemary Bastian,Nynke Ligtenberg,Vladislav Klyashtornyy,Benoît Callendret,Esther Heijnen,Archana Jastorff Arangassery Rosemary Bastian Nynke Ligtenberg Vladislav Klyashtornyy Benoît Callendret Esther Heijnen Janssen Vaccines & Prevention B.V.,Leiden,The NetherlandsArchana Jastorff obtained a PhD in proteomics and neurogenerative disease from the Max Planck Institute of Psychiatry and University of Tuebingen,Germany. She has 14 y of experience in clinical research and development of vaccines and was Study Responsible Scientist for RSV vaccine clinical studies at Janssen Vaccines & Prevention until recently. She is now Senior Clinical Science Lead at GSK.Arangassery Rosemary Bastian obtained a PhD in Biomedical Engineering from Drexel University. She has been at Janssen Inc for 6 y,as Director,Biomarkers Viral Vaccines,leading in particular the clinical biomarker strategy and immune response assessments for the RSV vaccine. She is now Director,Translational Sciences,at BioNTech SE.Nynke Ligtenberg obtained a Masters in Biomedical Sciences from Leiden University. She has 30 y of experience,including at Janssen Pharmaceuticals,where she had global operational oversight of the Janssen vaccines clinical research portfolio,and most recently acted as Clinical Development Leader of the RSV vaccine development program.Vladislav Klyashtornyy is an experienced biostatistician with more than 11 y of experience in supporting clinical phase 1 to phase 4 clinical studies. A doctor in medical chemistry from Krasnoyarsk State University,Russian Federation,with a further degree in molecular biology and biochemistry from Universite Evry Val d'Essone,France,he then trained as a biostatistician at the Institute for Statistical lead at Statistics.com,in the United States. He is Principal Biostatistician at IQVIA and Statistician lead for clinical programs at Janssen.Benoît Callendret is a Doctor in Veterinary Medicine (Ecole Nationale Vétérinaire de Toulouse) and has a PhD in Virology and Immunology (Institut Pasteur,Universite Paris VII). He has more than 10 y of experience as program development lead with vaccines,in particular as a Compound Development Team Leader at Janssen Vaccines & Prevention,where he led the RSV vaccine program. He is now Infectious Diseases & Vaccine Development Team Leader at Moderna.Esther Heijnen is a Medical Doctor specializing in gynecology. She has 20 years of experience of clinical development including 15 with vaccines. She was Senior Director,Global Clinical Development for respiratory vaccines at Janssen Vaccines & Prevention for 5 y,and she had in particular oversight of the clinical development of RSV vaccines. She is now Vice President,Clinical Development and R&D Co-lead for the vaccine therapeutic area leadership team with CSL Seqirus.

DOI: https://doi.org/10.1080/21645515.2024.2383504

2024-08-10

Human Vaccines & Immunotherapeutics

Abstract:The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)–related lower respiratory tract disease in a phase 2b study. This study compared the immunogenicity of vaccine clinical trial material (CTM) representative of phase 2b clinical studies with CTM used in phase 3 clinical studies. A total of 248 adults aged 60–75 years, randomized in a 1:1 ratio, received one dose of either phase 3 CTM or phase 2b CTM. Solicited adverse events (AEs), unsolicited AEs, and serious AEs (SAEs) were assessed for 7-d, 28-d, and 6-month periods post-vaccination, respectively. RSV preF-ELISA antibody titers and RSV neutralizing titers were measured before and 14 d after vaccination. The phase 3 CTM-induced preF-ELISA response at Day 15, in terms of geometric mean titer, was shown to be non-inferior to that induced by phase 2b CTM. The RSV neutralizing antibody titers were also similar in the two groups at Day 15. The safety profile in terms of solicited AEs, unsolicited AEs, or SAEs was in general similar between the phase 3 CTM and phase 2b CTM groups, and solicited AEs were mostly mild to moderate in intensity. No related SAEs were reported, and no safety concerns were identified.

immunology,biotechnology & applied microbiology